Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses governance updates by the American Board of Hair Restoration Surgery to improve transparency and professionalism, but it reports no new research findings.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

In this case report, researchers detailed a 22-year-old Turkish woman diagnosed with autosomal recessive woolly hair/hypotrichosis (ARWH/H), linked to a mutation in the LIPH gene, resulting in sparse, poorly growing, curly hair, highlighting the need for genetic consideration in similar hair conditions.

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

This systematic review reports that HAIR-AN syndrome, characterized by severe insulin resistance, hyperandrogenism, and distinctive skin issues, significantly impacts obese women and can improve with treatments like metformin, emphasizing the importance of targeted management to reduce metabolic complications.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study suggests that congenital atrichia with papular lesions may be more common than previously thought and proposes diagnostic criteria including the observation of hypopigmented whitish streaks on the scalp.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

People with alopecia areata may have a higher risk of hearing loss.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study reports cases of arterial embolization occurring due to the injection of hyaluronic acid (Restylane®).

This piece marks the tenth anniversary of the American Board of Hair Restoration Surgery and highlights the addition of 14 new diplomates from diverse countries, while reporting no new clinical findings.

This report describes a case of juvenile Rhupus syndrome in an 11-year-old girl, emphasizing the condition's rarity and the diagnostic challenges due to overlapping symptoms of juvenile idiopathic arthritis and systemic lupus erythematosus.

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This case report describes a 5-year-old girl with atrichia with papular lesions, whose diagnosis was confirmed through genetic testing identifying mutations in the hairless gene.

In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.

This review provides an overview of the hairless gene in mice and humans, discussing its structure, expression, and implications for understanding skin physiology and human disorders related to gene disruption, but it reports no new empirical findings.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

This study reports a case where subcutaneous aeroallergen immunotherapy led to hair regrowth in a child with seasonal alopecia areata linked to rhinitis and allergen sensitivity, maintaining results over four years with some residual symptoms.

This study found that alopecia areata patients with a CCHCR1 gene variant had higher recurrence rates and structural abnormalities in hair compared to those without the variant.

In this study, a novel E583V missense mutation in the hairless gene was identified in an Italian family with atrichia with papular lesions, reinforcing the significance of zinc-finger and LXXLL domains in this condition.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study describes a novel hairless mutant rat strain, F344-Hr(krh), developed via ENU mutagenesis, which provides a model for skin disease and potentially focal glomerulosclerosis due to specific genetic mutations.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study found significantly higher levels of the protein ULBP3 in patients with alopecia areata incognita compared to other hair loss conditions and healthy controls, suggesting ULBP3's potential as a diagnostic marker for AAI.

This article discusses initiatives by the ABHRS to enhance hair restoration surgery standards but presents no new research findings.